@article{3119476,
    title = "Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin chloride 10%",
    author = "Kontochristopoulos, G. and Markantoni, V. and Agiasofitou, E. and Platsidaki, E. and Kouris, A. and Campanati, A. and Offidani, A.M. and Rigopoulos, D. and Gregoriou, S.",
    journal = "Journal of the European Academy of Dermatology and Venereology",
    year = "2021",
    volume = "35",
    number = "8",
    pages = "e524-e526",
    publisher = "John Wiley and Sons Inc",
    issn = "0926-9959, 1468-3083",
    doi = "10.1111/jdv.17297",
    keywords = "glycopyrronium;  lisote cream;  oxybutynin;  sofipironium bromide;  umeclimidium;  unclassified drug;  mandelic acid derivative;  oxybutynin, comparative effectiveness;  cream;  Dermatology Life Quality Index;  disease severity assessment;  drug approval;  drug dosage form comparison;  drug efficacy;  drug safety;  human;  hyperhidrosis;  Japan;  Letter;  protein bound iodine;  quality of life;  treatment withdrawal;  United States;  urine incontinence;  axilla;  hyperhidrosis;  treatment outcome, Axilla;  Humans;  Hyperhidrosis;  Mandelic Acids;  Quality of Life;  Treatment Outcome"
}